Abstracts

RANKL Predicts 96-Week BMD Changes in ATV/r Monotherapy: A MODAt Trial Sub-Study

Background: To evaluate the association between bone biomarkers and changes in bone mineral density (BMD) over 96 weeks in patients treated with atazanavir/ritonavir (ATV/r) monotherapy vs ATV/r+2 N(t)RTIs. Methods: MODAt (NCT01511809) is a multicentric, randomized, open-label, non-inferiority trial. Patients on ATV/r 300/100mg+2 N(t)RTIs since≥48 weeks, virologically suppressed since≥24 weeks, randomized to ATV/r monotherapy (arm A)…

Predictors of Longitudinal Change in Bone Mineral Density in a Cohort of HIV Positive and Negative Subjects

Background: Although HIV infection is associated with low bone mineral density (BMD) in cross-sectional studies, whether it is associated with greater declines in BMD over time remains unclear. We aimed to compare rates of, and factors associated with, change in BMD over time between HIV-positive and -negative subjects, and to determine HIV-related predictors of change…

Heel Quantitative Ultrasound to Cut Down on DXA Costs in HIV-infected Patients

Background: HIV infection has been associated with increased risk of osteopenia/osteoporosis and fragility fractures. DXA is the reference standard to assess bone mass density (BMD), however it is a radiation-based and expensive technique, not easily accessible in several clinical settings. Quantitative ultrasound (QUS) of the heel is a radiation-free, easy-to-perform technique, which may help reducing…

Frailty and Cause-Specific Hospitalization Among Persons Aging With HIV and Drug Use

Background: Hospitalization events exact a substantial economic and clinical burden for aging HIV-infected populations. Frailty is a key aging-related syndrome, predictive of major adverse clinical outcomes, including all-cause hospitalization among older HIV-uninfected adults. We have previously reported the association of frailty with advanced HIV and mortality; however, limited data exist on the relationship of frailty…

Association of HIV Viral Load and Shorter Telomere Length

Background: Telomeres are DNA sequences on the ends of chromosomes that protect genomic integrity and shorten as cells age. Telomerase counteracts telomere shortening and prevents cellular aging. Telomerase may be inhibited by reverse transcriptase inhibitors and telomeres in T cells may be shortened by excess HIV-associated proliferation. Given association of HIV with CVD and other…

Novel Mechanisms of Nucleoside Analog Associated Mitochondrial DNA Mutation

Background: Mitochondrial DNA (mtDNA) mutation is a key feature of human aging. NRTI therapy may lead to accelerated accumulation of mtDNA mutations, but the mechanisms are unknown. Methods: We used a transmitochondrial cybrid cell line containing a single 7.5kb mtDNA deletion mutation, and fibroblasts from elderly individuals containing the m.414T>G point mutation. Cells were exposed…

Single-Variant Sequencing Revealed Rapid HCV Evolution in HIV Immune Reconstitution

Background: Human immunodeficiency virus (HIV) infection accelerates the progression of liver disease in Hepatitis C virus (HCV) co-infected individuals, raising the question of how immune status in co-infected individuals affects HCV quasispecies populations. We hypothesize that the structure and evolution of HCV populations in individuals with immune reconstitution differ from that in those with immune…

UNITY-1: Daclatasvir/Asunaprevir/Beclabuvir for HCV Genotype 1 Without Cirrhosis

Background: The all-oral combination of daclatasvir (DCV; pangenotypic NS5A inhibitor), asunaprevir (ASV; NS3 protease inhibitor), and beclabuvir (BCV; non-nucleoside NS5B inhibitor) achieved high rates of SVR12 in a phase 2 clinical trial. This regimen, in a twice-daily fixed-dose combination tablet—DCV-TRIO regimen—was evaluated without ribavirin in HCV genotype (GT) 1-infected treatment-naive and -experienced patients without cirrhosis…